CAD and pneumococcal infection: CPS-specific neutralizing antibodies were also found to mediate protection against pneumococcal infections (Finland and Sutliff, 1932), and the first CPS-based vaccine, targeting four S. pneumoniae serotypes, became available in 1945 (MacLeod et al., 1945).